Publicacións nas que colabora con María Teresa Pérez Álvarez (4)
2026
-
Corrigendum to “Real-World Impact of GLP-1 Receptor Agonists on Health-Related Quality of Life in Type 2 Diabetes and Obesity (SEVERAL Study)” [Clin Ther. 2026;48:291–293] (Clinical Therapeutics (2026) 48(7) (596–603), (S0149291826000743), (10.1016/j.clinthera.2026.03.012))
Clinical Therapeutics
-
Real-world Impact of GLP-1 Receptor Agonists on Health-related Quality of Life in Type 2 Diabetes and Obesity (SEVERAL Study)
Clinical Therapeutics, Vol. 48, Núm. 7, pp. 596-603
2025
-
Effects of GLP-1 agonists on 10-year cardiovascular risk reduction in primary prevention: A 44-week open label prospective study
Diabetes and Metabolic Syndrome: Clinical Research and Reviews, Vol. 19, Núm. 9
2023
-
Differences in weight loss and safety between the glucagon-like peptide-1 receptor agonists: A non-randomized multicenter study from the titration phase
Primary Care Diabetes, Vol. 17, Núm. 4, pp. 366-372